These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31855154)

  • 1. Intravenous ferric carboxymaltose is effective and safe in patients with inflammatory rheumatic diseases.
    Salvadori U; Vittadello F; Al-Khaffaf A; Maier A; Cappelletto PC; Daves M; Raffeiner B
    Blood Transfus; 2020 May; 18(3):176-181. PubMed ID: 31855154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.
    Mishra V; Gandhi K; Roy P; Hokabaj S; Shah KN
    J Nepal Health Res Counc; 2017 Sep; 15(2):96-99. PubMed ID: 29016575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    Stein J; Aksan A; Klemm W; Nip K; Weber-Mangal S; Dignass A
    J Crohns Colitis; 2018 Jun; 12(7):826-834. PubMed ID: 29955835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world efficacy and safety of intravenous ferric carboxymaltose for the management of iron deficiency anaemia in Malaysia: A single centre cohort study.
    Kamarul HNB
    Med J Malaysia; 2024 Sep; 79(5):517-524. PubMed ID: 39352152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
    Howaldt S; Domènech E; Martinez N; Schmidt C; Bokemeyer B
    Inflamm Bowel Dis; 2022 Mar; 28(3):373-384. PubMed ID: 33988236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Valério de Azevedo S; Maltez C; Lopes AI
    Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.
    Qunibi WY; Martinez C; Smith M; Benjamin J; Mangione A; Roger SD
    Nephrol Dial Transplant; 2011 May; 26(5):1599-607. PubMed ID: 20929915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial.
    Vanobberghen F; Lweno O; Kuemmerle A; Mwebi KD; Asilia P; Issa A; Simon B; Mswata S; Schmidlin S; Glass TR; Abdulla S; Daubenberger C; Tanner M; Meyer-Monard S
    Lancet Glob Health; 2021 Feb; 9(2):e189-e198. PubMed ID: 33245866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous ferric carboxymaltose for anaemia in pregnancy.
    Froessler B; Collingwood J; Hodyl NA; Dekker G
    BMC Pregnancy Childbirth; 2014 Mar; 14():115. PubMed ID: 24667031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of parenteral iron in children with inflammatory bowel disease.
    Papadopoulos M; Patel D; Korologou-Linden R; Goto E; Soondrum K; Fell JME; Epstein J
    Br J Clin Pharmacol; 2018 Apr; 84(4):694-699. PubMed ID: 29266387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
    Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP
    Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferric Carboxymaltose: A Review in Iron Deficiency.
    Scott LJ
    Drugs; 2018 Mar; 78(4):479-493. PubMed ID: 29532438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
    Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous ferric carboxymaltose versus oral ferrous sulphate for the treatment of moderate to severe postpartum anaemia in Nigerian women (IVON-PP): protocol for an open-label randomised controlled type 1 hybrid effectiveness-implementation trial.
    Afolabi BB; Adaramoye VO; Adeyemo TA; Balogun M; Mitchell EJ; Walker K; Akinajo OR; Abioye IA; Banke-Thomas A; Babah OA; Chieme CF; Oshodi Y; Quao R; Eboreime EA; Ogunsola F
    BMJ Open; 2024 Aug; 14(8):e086553. PubMed ID: 39153791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Controlled Trial of Intravenous Ferric Carboxymaltose vs Oral Iron to Treat Iron Deficiency Anemia After Variceal Bleed in Patients With Cirrhosis.
    Tabish M; Agarwal S; Gopi S; Rana R; Ahmed S; Gunjan D; Sharma S; Saraya A
    Am J Gastroenterol; 2024 Oct; 119(10):2061-2069. PubMed ID: 38517084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.